LinkGevity-led collaboration awarded UK Space Agency Grant

LinkGevity and Delta Biosciences, UAB, a Lithuanian pharmaceutical stability specialist, have been awarded funding from the UK Space Agency under the INTERNATIONAL BILATERAL FUND to prepare LinkGevity’s pioneering Anti-Necrotic therapeutic for deployment in space.

Astronauts face unique health challenges during spaceflight, including accelerated ageing and tissue degeneration driven by microgravity, radiation, and physiological stress. These changes mimic processes of biological decline seen in ageing on Earth.

The Anti-Necrotic is the first therapeutic capable of directly blocking necrosis—the destructive process of uncontrolled cell death that underpins tissue degeneration. By halting necrosis, it has the potential to protect astronaut health, combat accelerated ageing in space, and tackle a range of necrosis-driven diseases on Earth.

International collaboration and momentum

The UK–Lithuania partnership builds on both companies’ recognition as the only two non-US participants in NASA’s Space Health (Space-H) Programme in 2023.

LinkGevity and Delta formalised their collaboration with a Memorandum of Understanding (MoU) signed in Lithuania at the Baltic Biosciences conference, witnessed by international officials.

Dr Carina Kern said:

Necrosis has long been an unsolved challenge in medicine. Astronauts face accelerated degeneration and aging-linked conditions, and our therapeutic offers the first real chance to intervene in degeneration at its root. This award lets us prove readiness for space and transform treatment of age-related disease.

Dominykas Milasius, CEO of Delta, said:

Space creates biology’s toughest test. With LinkGevity we are advancing astronaut health and reshaping healthcare on Earth through international collaboration, driving innovations that extend human resilience on our planet and beyond.